文献速递基础与转化研究临床试验与 GCP

新辅助抗PD-1免疫治疗在复发性胶质母细胞瘤中促进生存获益并增强瘤内及全身免疫反应

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
PubMed 文献 · Nat Med · 2019-02-11

这项随机多机构临床试验在35例复发性可手术胶质母细胞瘤患者中评估新辅助和/或辅助帕博利珠单抗治疗的免疫反应与生存。新辅助帕博利珠单抗联合术后持续辅助治疗较单纯术后辅助PD-1阻断显著延长总生存。新辅助PD-1阻断与瘤内T细胞及干扰素-γ相关基因表达上调、细胞周期相关基因表达下调相关。

要点

  • 新辅助帕博利珠单抗联合辅助治疗较单纯辅助PD-1阻断显著延长复发性胶质母细胞瘤总生存。
  • 新辅助PD-1阻断上调瘤内T细胞和干扰素-γ相关基因表达,下调细胞周期相关基因表达。
  • 新辅助组更常见肿瘤微环境PD-L1局灶诱导、T细胞克隆扩增增强及外周血T细胞PD-1表达下降。

核心结论

  • 新辅助PD-1阻断可增强局部和全身抗肿瘤免疫反应,可能为复发性胶质母细胞瘤更有效的治疗方式。

研究设计与样本

  • Ivy Foundation早期临床试验联盟开展的随机多机构临床试验,纳入35例复发性可手术胶质母细胞瘤患者,评估新辅助和/或辅助帕博利珠单抗治疗的免疫反应与生存。

主要发现

  • 随机接受新辅助帕博利珠单抗并术后持续辅助治疗的患者,总生存较随机接受单纯术后辅助PD-1阻断者显著延长。
  • 新辅助PD-1阻断与瘤内T细胞及干扰素-γ相关基因表达上调、细胞周期相关基因表达下调相关,单纯辅助治疗未见此变化。
  • 新辅助组较单纯辅助组更常见肿瘤微环境PD-L1局灶诱导、T细胞克隆扩增增强、外周血T细胞PD-1表达下降及单核细胞群减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical programmed cell death protein 1 (PD-1) blockade alone. Neoadjuvant PD-1 blockade was associated with upregulation of T cell- and interferon-γ-related gene expression, but downregulation of cell-cycle-related gene expression within the tumor, which was not seen in patients that received adjuvant therapy alone. Focal induction of programmed death-ligand 1 in the tumor microenvironment, enhanced clonal expansion of T cells, decreased PD-1 expression on peripheral blood T cells and a decreasing monocytic population was observed more frequently in the neoadjuvant group than in patients treated only in the adjuvant setting. These findings suggest that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019. PMID: 30742122. doi:10.1038/s41591-018-0337-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。